Frontlight ResearchEarly access
Not yet recruitingPhase 1
A randomized, placebo-controlled, single-blind phase 1 trial to evaluate safety, pharmacokinetics and pharmacodynamics of subcutaneously administered RBD3133 in healthy participants with overweight/obesity
Key facts
- Who runs it
- Ribocure Pharmaceuticals AB
- Where
- Sweden1 site in 1 countryChoose a country to see its sites
- Trial code
- EU 2026-525607-27-00
- U1111-1340-5093
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 80 people, planned
- Starts
- 14 Dec 2026
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional
- Record updated
- 13 November 2026
Who can take part
- Age
- 18 years to 64 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Criteria questions
- Built from 2026-525607-27-00, who can take part
- Record updated
- 13 November 2026